Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M776Revenue (TTM) $M--Net Margin (%)--Altman Z-Score
Enterprise Value $M-95.3EPS (TTM) $--Operating Margin %--Piotroski F-Score--
P/E(ttm)20.4Beneish M-Score--Pre-tax Margin (%)--Higher ROA y-yN
Price/Book3.010-y EBITDA Growth Rate %--Quick Ratio--Cash flow > EarningsN
Price/Sales--5-y EBITDA Growth Rate %--Current Ratio--Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)--Higher Current Ratio y-yN
Dividend Yield %0.9PEG--ROE % (ttm)--Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M13,050,000ROIC % (ttm)--Gross Margin Increase y-yN

Gurus Latest Trades with PJP

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

PJP is held by these investors:



PJP: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Rapps, MichaelDirector, Director or Senior Officer of 10% Securi 2017-01-16Buy1,200$9.48530.59view
Gridley, Anthony RonaldSenior Officer 2017-01-16Sell1,800$16.94252.89view
Dinwoodie, Tyler Wayne PaulSenior Officer 2017-01-16Buy4,000$0.1735064.71view
Brown, Mark ThomasDirector 2017-01-16Sell29,300$1.364295.59view
Bebek, IvanDirector 2017-01-16Buy8,990$3.381668.64view
smith, laurie james10% Security Holder, Director, Senior Officer 2017-01-16Buy7,500$0.4114480.49view
MEHR, JEFFREYSenior Officer 2017-01-13Sell50,000$27.91114.19view
Squibb, Geoffrey WayneDirector 2017-01-13Buy267$6.27853.43view
Smith, DavidSenior Officer 2017-01-13Sell15,000$60.38-0.99view
Rowlands, William BruceDirector, Senior Officer 2017-01-13Buy20,000$0.1539753.33view

Quarterly/Annual Reports about PJP:

    News about PJP:

    Articles On GuruFocus.com
    No related article found.

    More From Other Websites
    Bausch & Lomb Continues to be Key Growth Driver for Valeant Mar 24 2017
    New Product Launches May Boost Valeant’s Dermatology Revenue Mar 23 2017
    Relistor May Be Solid Growth Opportunity for Valeant in 2017 Mar 22 2017
    Trump, Biogen and Amgen Hammer Healthcare ETFs Mar 20 2017
    Should You Buy Pharma ETFs Now? Mar 15 2017
    [$$] Drug Stocks Look Ready To Move Higher Mar 15 2017
    Trump’s ‘Obamacare Lite’ presents opportunities and perils for investors Mar 09 2017
    Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs Mar 08 2017
    How Mylan’s Europe Segment Performed Mar 03 2017
    Hit ETFs & Stocks from the Top Sector of February Mar 01 2017
    Eli Lilly & Co.’s Recent Developments Feb 28 2017
    Keytruda: Merck & Co.’s Immuno-Oncology Blockbuster Drug Feb 22 2017
    Trending: Financials Trade Sideways as Trump Prepares Dodd-Frank Rollback Feb 09 2017
    Q4 Earnings Faring Well for Pharma ETFs Feb 06 2017
    Changes in Bristol-Myers Squibb’s 4Q16 Profitability Feb 01 2017
    Why Eli Lilly Expects to See Revenue Growth in 4Q16 Jan 25 2017
    What Lies Ahead for Pharma ETFs? Jan 19 2017
    Trending: Pound Gains as Theresa May Lays out Brexit Plan Jan 19 2017
    Mylan’s Profit Margins: What Made Them Change? Jan 13 2017
    Understanding Mylan’s Revenues Jan 12 2017

    Add Notes, Comments

    If you want to ask a question or report a bug, please create a support ticket.
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)